Russia’s Rusatom to co-operate with Indian companies for nuclear in healthcare
“Rusatom Healthcare is going to co-operate with local companies for delivery of high technology solutions in medicine which will greatly enhance the efficiency of diagnostics in particularly oncological cases,” said Sergey Evdonin, Project Head, Rosatom Healthcare while answering to a question of mojo4industry during a webinar organized by Rosatom for journalists from India and Bangladesh. According to Russian expert JSC Rusatom Healthcare, nuclear medicine is increasingly becoming crucial for diagnostics and therapy including thyroid owing to rapid innovations in technology.
In the webinar, Mr. Evdonin explained how nuclear medicine technology is being increasingly adopted across the world and demand for nuclear medicine products and solutions have seen rapid growth. Catering to this demand, Rusatom Healthcare, an integrator of the radiation technologies for medicine and industry within Rosatom, offers a range of products with integrated solutions spanning project concept and development, design, construction, equipment manufacturing and supply, supply and installation of equipment, training of personnel, and service and maintenance.
Elaborating upon the products and solutions, Mr. Evdonin added that broadly, Rusatom Healthcare offers products and solutions in three broader categories; Diagnostic facilities, Therapeutic facilities, and Integrated solutions for GMP standard radiopharmaceutical production. In addition to off-the-shelf offerings, the solutions can be optimized and configured as per the needs of the customer.
Highlighting the benefits of the products, Mr. Evdonin stated that Positron emission tomography (PET) diagnostics have proven to improve a number of indicators including 5-6 times decrease in the number of cancer recurrences, 15-20% increase in the number of detected cancer cases, 30-40% quality improvement of cardiovascular disease diagnostics, 5-30% reduction in cancer mortality through correct treatment. In terms of therapeutic for nuclear medicine, Rusatom Healthcare’s products for Radionuclide therapy, Radiotherapy, Brachytherapy and Proton and ion beam therapy are being widely used across the world. Rusatom Healthcare JSC provides radiopharmaceuticals for molecular imaging, radionuclide therapy and diagnostics and supplies isotope products to more than 50 countries enabling diagnosis and treatment of about 2.5 million people every year.